- S. Korea approves Celltrion Inc.’s COVID-19 antibody treatment with conditions.
- The country’s drug safety agency has given conditional marketing authorization of CT-P59.
- Celltrion plans to conduct a global phase-three clinical trial in more than 10 countries.
- The antibody treatment candidate will be used for people at higher risk, mostly to peopl....
Tags : SOUTH KOREA COVID-19, CELLTRION INC., COVID-19 ANTIBODY TREATMENT, SOUTH KOREA MINISTRY OF FOOD AND DRUG SAFETY, CELLTRION CT-P59, SOUTH KOREA COVID-19 TREATMENT, EMERGENCY USE AUTHORIZATION,